Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCEP vs DCEP + Thalidomide in Relapsed Multiple Myeloma
NCT00083681Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jun 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoint: Effectiveness of DCEP +/- Thalidomide. Started Jun 1998; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00083681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083681.